SS-31 is a small peptide that selectively targets the inner mitochondrial membrane, binding to cardiolipin to stabilize mitochondrial structure and function. This enhances ATP production and reduces oxidative stress, directly addressing the age-related decline in mitochondrial health, a core driver of aging. Its potential lies in restoring cellular energy and function in tissues with high energy demands, like the heart, brain, and muscles.
Verdict
A promising but high-risk experimental peptide for mitochondrial restoration.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
C
MONTHLY COST
$400 - $1200
Protocol
- Daily subcutaneous injections of 4-10 mg are explored in research contexts.
Flags
- Not approved for human use by the FDA; sourced as a 'research chemical'.
- Long-term safety profile for healthspan purposes is unknown.
- Requires subcutaneous injection, which carries risks of infection and improper administration.
- Purity and dosage accuracy from unregulated suppliers can be highly variable.